These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study. Lirhus SS; Høivik ML; Moum B; Melberg HO Scand J Gastroenterol; 2018 Aug; 53(8):952-957. PubMed ID: 30205699 [TBL] [Abstract][Full Text] [Related]
43. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816 [TBL] [Abstract][Full Text] [Related]
44. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286 [TBL] [Abstract][Full Text] [Related]
45. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. Cohen BL; Sachar DB BMJ; 2017 Jun; 357():j2505. PubMed ID: 28630047 [TBL] [Abstract][Full Text] [Related]
46. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Heuschkel R; Salvestrini C; Beattie RM; Hildebrand H; Walters T; Griffiths A Inflamm Bowel Dis; 2008 Jun; 14(6):839-49. PubMed ID: 18266237 [TBL] [Abstract][Full Text] [Related]
47. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184 [TBL] [Abstract][Full Text] [Related]
48. [Contemporary methods of the surgical treatment of nonspecific inflammatory bowel diseases]. Paśnik K; Krupa J; Stanowski E Pol Merkur Lekarski; 2004; 17 Suppl 1():44-6. PubMed ID: 15603346 [TBL] [Abstract][Full Text] [Related]
49. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. de Mattos BR; Garcia MP; Nogueira JB; Paiatto LN; Albuquerque CG; Souza CL; Fernandes LG; Tamashiro WM; Simioni PU Mediators Inflamm; 2015; 2015():493012. PubMed ID: 26339135 [TBL] [Abstract][Full Text] [Related]
50. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Florholmen J Scand J Gastroenterol; 2015 Jan; 50(1):43-52. PubMed ID: 25523555 [TBL] [Abstract][Full Text] [Related]
51. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478 [TBL] [Abstract][Full Text] [Related]
52. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708 [TBL] [Abstract][Full Text] [Related]
53. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751 [TBL] [Abstract][Full Text] [Related]
54. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573 [TBL] [Abstract][Full Text] [Related]